Biosynthesis of the anti‐diabetic metabolite montbretin A: glucosylation of the central intermediate mini‐MbA

Type 2 diabetes (T2D) affects over 320 million people worldwide. Healthy lifestyles, improved drugs and effective nutraceuticals are different components of a response against the growing T2D epidemic. The specialized metabolite montbretin A (MbA) is being developed for treatment of T2D and obesity...

Descripción completa

Detalles Bibliográficos
Autores principales: Irmisch, Sandra, Jancsik, Sharon, Yuen, Macaire M. S., Madilao, Lufiani L., Bohlmann, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899944/
https://www.ncbi.nlm.nih.gov/pubmed/31400245
http://dx.doi.org/10.1111/tpj.14493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899944/
https://www.ncbi.nlm.nih.gov/pubmed/31400245
http://dx.doi.org/10.1111/tpj.14493

Ejemplares similares